Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on January 31, 2023, primarily announcing the upcoming departure of a key board member, Donna A. James. Ms. James, who has served on the Board of Directors since July 2015 and holds significant committee roles including Chair of the Executive Compensation and Human Resources Committee, will not seek re-election at the company's 2023 Annual Meeting scheduled for May 4, 2023. Her departure is not attributed to any disagreements with the company, providing a smooth transition for the Board. This change will reduce the Board's size from ten to nine directors following the annual meeting, assuming no other changes. The company's Board and Nominating and Governance Committee will continue to assess the optimal size and composition of the Board moving forward. Investors should note this change in Board composition, though it appears to be a planned transition without adverse implications.
Key Highlights
- 1Director Donna A. James will not stand for re-election at the 2023 Annual Meeting.
- 2Ms. James has served on the Board since July 2015.
- 3She currently chairs the Executive Compensation and Human Resources Committee.
- 4Ms. James is also a member of the Nominating and Governance Committee.
- 5Her departure is effective following the 2023 Annual Meeting on May 4, 2023.
- 6Ms. James' decision is not due to any disagreement with Boston Scientific.
- 7The Board size will decrease from ten to nine directors post-annual meeting.